Mercer Global Advisors
MIST icon

Mercer Global Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Mercer Global Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,100
Closed -$29.3K – 2701
2025
Q2 		$29.3K Buy
+15,100
New +$20.1K ﹤0.01% 2215

Other funds holding MIST

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Mercer Global Advisors's MIST Position: Q3 2025 in Review

Mercer Global Advisors sold out of Milestone Pharmaceuticals (MIST) in Q3 2025, closing a stake of 15,100 shares — an estimated $29.3K sold.

Mercer Global Advisors first reported a position in MIST in Q2 2025 and held it in 1 quarter. The position peaked at $29.3K in Q2 2025. 61 funds tracked by Wall St. Rank hold MIST as of Q3 2025.

  • Mercer Global Advisors reported no remaining Milestone Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Mercer Global Advisors sold 15,100 Milestone Pharmaceuticals shares in Q3 2025, an estimated $29.3K.
  • Mercer Global Advisors first reported a position in Milestone Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Mercer Global Advisors's Milestone Pharmaceuticals position peaked at $29.3K in Q2 2025.
  • 61 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2025.

Based on Mercer Global Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.